Predictive Models of Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy.
- Male or female > 18 years
- Histologically confirmed solid tumor.
- Subjects who have not received chemotherapy and / or radiotherapy in the last 3
- Subject to initiate a chemotherapy (ie, cycle 1, day 1)
- The chemotherapy regimen should have an inherent risk of febrile neutropenia of
- Planning a minimum of 3 cycles chemotherapy.
- Adequate bone marrow reserve defined by: leukocytes ≥ 3,000 / mm3, platelets ≥
100.000/mm3; neutrophils ≥ 1,500 / mm3.
- Adequate hepatic and renal function, defined by: bilirubin <1.5 times the normal
value, ALT and AST <3 times the normal range (both can be elevated up to 5 times the
normal value in patients with known liver metastases); creatinine <1.5 times upper
- ECOG ≤ 2.
- Informed consent
- Patients under treatment with an investigational treatment.
- Active infection in the last 72 h before starting chemotherapy.
- Indication of chemotherapy dose intensity or chemotherapy included in the risk rating
of febrile neutropenia <10% or >20%.
- Patients with concomitant chemoradiotherapy.
- Patients being treated with biological drugs in monotherapy.
- Any other condition causing neutropenia.
- History of bone marrow transplant or stem cells.